Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Regenxbio Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
RGNX
Nasdaq
8731
https://regenxbio.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Regenxbio Inc
REGENXBIO Sees Positive Results For Macular Degeneration Therapy
- Mar 28th, 2024 5:09 pm
REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD
- Mar 28th, 2024 11:05 am
REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days
- Mar 27th, 2024 8:05 pm
Regenxbio Inc (RGNX) President and CEO Kenneth Mills Sells 15,000 Shares
- Mar 18th, 2024 11:00 pm
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
- Mar 13th, 2024 12:00 pm
REGENXBIO to Participate in Upcoming Investor Conferences
- Mar 11th, 2024 11:05 am
Regenxbio Inc (RGNX) Chief Medical Officer Steve Pakola Sells 12,878 Shares
- Mar 8th, 2024 6:29 am
Bearish: Analysts Just Cut Their REGENXBIO Inc. (NASDAQ:RGNX) Revenue and EPS estimates
- Mar 7th, 2024 7:03 pm
REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants
- Mar 7th, 2024 4:20 am
REGENXBIO Announces Proposed Public Offering of Common Stock
- Mar 6th, 2024 9:10 pm
REGENXBIO (RGNX) Soars 15% on Interim Data From DMD Study
- Mar 6th, 2024 4:33 pm
Regenxbio data suggest ‘niche’ in Duchenne gene therapy
- Mar 6th, 2024 8:01 am
REGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE® TRIAL
- Mar 5th, 2024 12:05 pm
REGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® Trial
- Feb 29th, 2024 9:30 pm
Q4 2023 Regenxbio Inc Earnings Call
- Feb 28th, 2024 4:05 pm
REGENXBIO Inc. (NASDAQ:RGNX) Q4 2023 Earnings Call Transcript
- Feb 28th, 2024 2:36 pm
Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates
- Feb 27th, 2024 10:35 pm
Regenxbio Inc (RGNX) Reports Full Year 2023 Financial Results and Operational Highlights
- Feb 27th, 2024 9:41 pm
REGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
- Feb 27th, 2024 9:05 pm
REGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
- Feb 21st, 2024 12:05 pm
Scroll